Pfizer Stock Quote Today

PFE
 Stock
  

USD 51.59  1.50  2.99%   

Market Performance
0 of 100
Odds Of Distress
Less than 14
Pfizer is trading at 51.59 as of the 27th of June 2022, a 2.99 percent up since the beginning of the trading day. The stock's lowest day price was 50.3. Pfizer has less than a 14 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. Equity ratings for Pfizer Inc are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 7th of July 2020 and ending today, the 27th of June 2022. Click here to learn more.
CUSIP
717081103
Fiscal Year End
December
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
13th of August 2012
Category
Healthcare
Classification
Health Care
ISIN
US7170811035
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. The company has 5.61 B outstanding shares of which 67.99 M shares are at this time shorted by investors with about 2.71 days to cover. More on Pfizer Inc
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Pfizer Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Pfizer's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Pfizer or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
About 70.0% of the company shares are owned by institutional investors
Latest headline from www.marketwatch.com: Incyte Corp. stock outperforms market on strong trading day - MarketWatch
ESG SustainabilitySome studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary, Pfizer's sustainability indicators can be used to identify a proper investment strutegies using environmental, social, and governance scores that are crucial to Pfizer's managers, analysts, and investors.
Environment Score
Governance Score
Social Score
ChairmanIan Read
Thematic Ideas
(view all).
Excise Tax ActivitiesAnimal TestingCatholic
Average Analyst Recommendation
Analysts covering Pfizer report their recommendations after researching Pfizer's financial statements, talking to executives and customers, or listening in on Pfizer's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Pfizer Inc. The Pfizer consensus assessment is calculated by taking the average forecast from all of the analysts covering Pfizer.
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Pfizer Inc based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Pfizer Inc financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 6 - HealthyDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares7.1 B6.4 B
Moderately Up
Decreasing
Slightly volatile
Weighted Average Shares Diluted7.2 B6.5 B
Moderately Up
Decreasing
Slightly volatile
Net Cash Flow from Operations17.8 B16.6 B
Significantly Up
Decreasing
Very volatile
Total Assets193.5 B177.4 B
Significantly Up
Decreasing
Slightly volatile
Total Liabilities113.9 B104.6 B
Significantly Up
Decreasing
Very volatile
Current Assets49.4 B40.3 B
Fairly Up
Decreasing
Slightly volatile
Current Liabilities24.4 B23.3 B
Sufficiently Up
Increasing
Very volatile
Total Debt55.8 B60 B
Significantly Down
Increasing
Slightly volatile
Return on Average Assets5.835.38
Significantly Up
Increasing
Very volatile
Gross Margin70.8671.33
Slightly Down
Decreasing
Slightly volatile
Asset Turnover0.340.3
Moderately Up
Decreasing
Stable
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Pfizer's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong BuyUndervalued
Financial Strength
Pfizer's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Pfizer's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Pfizer's bond ratings measure its overall creditworthiness, which in many ways corresponds to the cost of borrowing for an issuer. These ratings assign a letter grade to all of Pfizer's outstanding corporate bonds that indicate their credit quality. We use reports published by private self-sufficient rating services such as Standard & Poor's or Fitch Ratings Inc. to evaluate a bond issuer's financial strength or its ability to pay a bond's principal and interest.
N/A ( Average Bond Rating ) Not Rated
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Pfizer's financial leverage. It provides some insight into what part of Pfizer's total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Pfizer's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Pfizer deploys its capital and how much of that capital is borrowed.
Liquidity
Pfizer cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company has 41.39 B in debt with debt to equity (D/E) ratio of 0.53, which is OK given its current industry classification. Pfizer Inc has a current ratio of 1.37, which is typical for the industry and considered as normal. Debt can assist Pfizer until it has trouble settling it off, either with new capital or with free cash flow. So, Pfizer's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Pfizer Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Pfizer to invest in growth at high rates of return. When we think about Pfizer's use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

17.83 BillionShare
Pfizer Inc (PFE) is traded on New York Stock Exchange in USA and employs 79,000 people. The company currently falls under 'Mega-Cap' category with total capitalization of 270.04 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Pfizer's market, we take the total number of its shares issued and multiply it by Pfizer's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Pfizer Inc runs under Healthcare sector within Drug Manufacturers—General industry. The entity has 5.61 B outstanding shares of which 67.99 M shares are at this time shorted by investors with about 2.71 days to cover. Pfizer Inc has about 31.07 B in cash with 32.58 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.53.
Check Pfizer Probability Of Bankruptcy
Ownership
Pfizer Inc has a total of 5.61 Billion outstanding shares. Over half of Pfizer Inc outstanding shares are owned by third-party entities. These third-party entities are typically referred to corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulation than regular investors in Pfizer. Please watch out for any change in the institutional holdings of Pfizer Inc as this could mean something significant has changed or about to change at the company. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.

Ownership Allocation (%)

Check Pfizer Ownership Details

Pfizer Stock Price Odds Analysis

What are Pfizer's target price odds to finish over the current price? Based on a normal probability distribution, the odds of Pfizer jumping above the current price in 90 days from now is about 28.94%. The Pfizer Inc probability density function shows the probability of Pfizer stock to fall within a particular range of prices over 90 days. Considering the 90-day investment horizon Pfizer has a beta of 0.78 indicating as returns on the market go up, Pfizer average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Pfizer Inc will be expected to be much smaller as well. Additionally, the company has an alpha of 0.3068, implying that it can generate a 0.31 percent excess return over DOW after adjusting for the inherited market risk (beta).
  Odds Below 51.59HorizonTargetOdds Above 51.59
70.82%90 days
 51.59 
28.94%
Based on a normal probability distribution, the odds of Pfizer to move above the current price in 90 days from now is about 28.94 (This Pfizer Inc probability density function shows the probability of Pfizer Stock to fall within a particular range of prices over 90 days) .

Pfizer Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Pfizer that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Pfizer's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Pfizer's value.
InstituionSecurity TypeTotal SharesValue
Vanguard Group IncCommon Shares479.1 M24.8 B
Blackrock IncCommon Shares408.1 M21.1 B
View Pfizer Diagnostics

Pfizer Historical Income Statement

Pfizer Inc Income Statement is one of the three primary financial statements used for reporting Pfizer's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Pfizer Inc revenue and expense. Pfizer Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Pfizer Cost of Revenue is projected to decrease significantly based on the last few years of reporting. The past year's Cost of Revenue was at 9.2 Billion. The current year Gross Profit is expected to grow to about 37.7 B, whereas Earning Before Interest and Taxes EBIT is forecasted to decline to about 18.5 B. View More Fundamentals

Pfizer Stock Against Markets

Picking the right benchmark for Pfizer stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Pfizer stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Pfizer is critical whether you are bullish or bearish towards Pfizer Inc at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Pfizer without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Center Now

   

Portfolio Center

All portfolio management and optimization tools to improve performance of your portfolios
All  Next Launch Module

Pfizer Corporate Directors

Pfizer corporate directors refer to members of a Pfizer board of directors. The board of directors generally takes responsibility for the Pfizer's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Pfizer's board members must vote for the resolution. The Pfizer board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Helen Hobbs - Independent DirectorProfile
Shantanu Narayen - Lead Independent DirectorProfile
James Smith - Independent DirectorProfile
Dennis Ausiello - Independent DirectorProfile

Investing Pfizer Inc

You need to understand the risk of investing before taking a position in Pfizer. The danger of trading Pfizer Inc is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Pfizer is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Pfizer. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Pfizer Inc is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Please check Your Equity Center. Note that the Pfizer Inc information on this page should be used as a complementary analysis to other Pfizer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

Complementary Tools for Pfizer Stock analysis

When running Pfizer Inc price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Is Pfizer's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
0.59
Market Capitalization
289.5 B
Quarterly Revenue Growth YOY
0.77
Return On Assets
0.12
Return On Equity
0.34
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine Pfizer value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.